DiagnoCure Inc. is a Canada-based biotechnology company. The Company is engaged in the development and commercialization of products indicated for the diagnosis of cancer. The Company develops and provides molecular and genomic tests to support effective clinical decisions enabling personalized medicine in oncology. The Company’s prostate cancer marker PROGENSA PCA3 is a tool for the diagnosis and management of prostate cancer patients. The Company’s products also include Previstage GCC colorectal cancer staging test, which uses Guanylyl Cyclase C (GCC or GUCY2C) marker to stratify the risk of colon cancer recurrence by determining the stage of the disease. The Company’s subsidiaries include Catalyst Oncology LP, 9184‐6766 Quebec Inc. and 9161‐6722 Quebec Inc.